-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-011 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-011 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-011 in Systemic Sclerosis (Scleroderma) Drug Details: FT-011 (SHP-627) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maplirpacept in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Lymphoma Drug Details: Maplirpacept (TTI-622) is under development for the...
-
Product Insights
NewFocal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024
Empower your strategies with our Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024 report and make more profitable business decisions. Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name "focal segmental". FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...
-
Product Insights
NewSystemic Sclerosis (Scleroderma) – Drugs In Development, 2024
Empower your strategies with our Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024 report and make more profitable business decisions. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pain, joint pain and swelling, ulcers occurring on the fingertips, bloating, and diarrhea or constipation. Treatment includes antibiotics, pain relievers, and immunosuppressants. The Systemic Sclerosis (Scleroderma) drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewChronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewInterstitial Lung Fibrosis – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...
-
Sector Analysis
United Kingdom (UK) Forecourt Market Size and Forecast by Segment and Fuel Retailer Profiles to 2027
UK Forecourt Market Report Overview The total forecourt sales in the UK was GBP66.96 billion in 2022 and the market is expected to record a CAGR of more than 1% during 2023-2027. Customer demand for convenience is driving the forecourt product and service offerings by fuel companies. UK Forecourt Market Outlook, 2022-2027 (GBP Billion) Buy the Full Report for Additional Insights on the UK Forecourt Market Forecast Download a Free Sample Report The UK Forecourt market research report is invaluable...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986104 in Rheumatoid Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986104 in Rheumatoid Arthritis Drug Details: BMS-986104 is under development for the treatment of atopic...